Suggestions
Ricardo Perdigão Henriques, PhD
Managing Partner at Biovance Capital | Harvard/MIT-educated PhD scientist
Ricardo Perdigão Henriques, PhD is the Co-Founder and Managing Partner of Biovance Capital, a new venture capital firm focused on early-stage biotech investments.13 Here are some key details about his background and role:
Professional Experience
Ricardo is a Harvard and MIT-educated scientist who transitioned into venture capital and entrepreneurship.24 He has over 18 years of experience in the life sciences sector, spanning biomedical research, pharmaceutical business development, and venture capital in both the USA and Portugal.2
Current Role
As Managing Partner at Biovance Capital, Ricardo leads the identification of new investment opportunities and manages the firm's portfolio companies.3 He played a crucial role in establishing Biovance Capital Fund I, which recently announced its first closing at €51 million.1
Educational Background
- PhD in Molecular Oncology
- BSc in Biochemistry
- Educated at prestigious institutions including Harvard Medical School and MIT24
Prior Experience
Before co-founding Biovance Capital, Ricardo served as the CEO of Bionova Capital from 2019 to 2024.2 His diverse background includes publications in high-ranking scientific journals such as the Journal of Clinical Investigation and Oncogene.2
Vision and Impact
Ricardo is committed to developing Portugal's biomedical ecosystem and supporting innovative biotech companies across Europe, with a special focus on Southern Europe.1 His leadership at Biovance Capital aims to provide crucial capital and support for the development of novel transformational therapies addressing unmet medical needs.1
Highlights
Excited to announce that the seemingly impossible dream of building a healthcare-specialized VC fund in Portugal has finally come true! We announced today Biovance Capital Fund I, our new € 51 million biotech fund to invest in disruptive early-stage drug development companies across Europe.
I am thrilled to contribute to the growth of the European biotech ecosystem alongside our talented team, including Joao Incio, MD PhD and André Albergaria. We look forward to partnering with visionary founders and supporting the next generation of life-changing therapies.
A heartfelt thank you to our supporters, including the European Investment Fund (EIF), Banco Português de Fomento, Caixa Capital, SCR, S.A., Grupo Ageas Portugal, and private investors from the US and Europe.
Press release here: https://lnkd.in/dY45WyjE
Subscribe to our newsletter: https://lnkd.in/dGQxq-3k
#VentureCapital #Biotech #Healthcare #Innovation #Portugal #Europe #startups #BiovanceCapital
Thrilled to announce that our exit from CellmAbs has been recognized with the prestigious Investment of the Year award by the Portuguese Investment Association INVESTORS PORTUGAL, together with Portugal Ventures!
This landmark deal done during my tenure at Bionova Capital has set a new benchmark in Portugal's venture capital landscape: 🏆 Largest venture exit in Europe during Q1 2024 (as reported by Pitchbook) 🚀 Showcasing the potential of Portuguese biotech on the global stage
Congratulations to CellmAbs' founders NUNO Prego Ramos and Paula Videira! This success underscores Portugal's growing prominence in the biotech sector and highlights the impact of collaborative efforts between investors and innovators.
Stay tuned for major developments from Biovance Capital in the coming weeks!
#VentureCapital #BiotechInnovation #PortugueseStartups #InvestmentSuccess #BionovaCapital
